Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus

Study:

Evaluation of Mitomycin, Doxorubicin and Cisplatin in the Treatment of Recurrent or Advanced Uterine Sarcomas

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

Purpose:

Phase II trial to study the effectiveness of combination chemotherapy with mitomycin, doxorubicin, and cisplatin in treating patients with recurrent or advanced cancer of the uterus.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Sarcoma Drug: cisplatin
Drug: doxorubicin hydrochloride
Drug: mitomycin C		 Phase 2

Verified by Gynecologic Oncology Group May, 2006

Sponsored by: Gynecologic Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00002993

Study Type: Interventional

Study Design: Treatment

Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States

John H. Edmonson, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.